Catalyst Pharmaceuticals (FRA:CN2) Construction In Progress: €0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CN2 Catalyst Pharmaceuticals Inc FRA:CN2
93 GF Score
Price €27.30
GF Value €20.73
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Catalyst Pharmaceuticals Construction In Progress?

Catalyst Pharmaceuticals FRA:CN2 93 Construction In Progress is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:CN2 with a GF Score™ of 93/100 and a GF Value™ of €20.73 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Catalyst Pharmaceuticals Construction In Progress Historical Data

* Premium members only.

The historical data trend for Catalyst Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals Construction In Progress Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Catalyst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:CN2
93GF Score
Catalyst Pharmaceuticals Inc FRA:CN2
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Catalyst Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0.0 Mil mean?
Catalyst Pharmaceuticals (FRA:CN2) has a Construction In Progress of €0.0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Catalyst Pharmaceuticals and its competitors.
Is Catalyst Pharmaceuticals' Construction In Progress too high?
Catalyst Pharmaceuticals' current Construction In Progress is €0.0 Mil. Overall, Catalyst Pharmaceuticals has a GF Score™ of 93/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' Construction In Progress compare to CRNX and NAMS?
Catalyst Pharmaceuticals' Construction In Progress of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Catalyst Pharmaceuticals and its competitors. Catalyst Pharmaceuticals's current Construction In Progress is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (FRA:CN2) is currently considered Significantly Overvalued. The stock's GF Value™ is €20.73, compared to a current price of €27.30 — trading 31.7% above its estimated fair value. The current Construction In Progress is €0.0 Mil. Catalyst Pharmaceuticals' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Catalyst Pharmaceuticals (FRA:CN2), the current Construction In Progress is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Catalyst Pharmaceuticals (FRA:CN2) Overvalued in 2026?

Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued. The current stock price of €27.30 is trading 31.7% above its estimated GF Value™ of €20.73. GuruFocus considers Catalyst Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:CN2:

  • Construction In Progress: €0.0 Mil
  • GF Value™: €20.73 vs. price of €27.30 (31.7% above fair value)
  • GF Score™: 93/100 with 6 warning signs

No single metric tells the full story. See the FRA:CN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Catalyst Pharmaceuticals Business Description

Other Exchanges CPRX:USACN2:Germany
Address 355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
93GF Score

Get the complete analysis for FRA:CN2

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.30
Price
€20.73
GF Value